Press releases
* (R) = Regulatory press releases
22 Sep, 2021
(R) Cantargia: FDA grants Orphan Drug Designation to nadunolimab for treatment of pancreatic cancer
16 Sep, 2021
(R) Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress
10 Sep, 2021
(R) Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study
30 Aug, 2021